Table 5.
Multivariate survival analysis of PFS and OS in 70 patients with endometrial carcinoma.
| HR | 95% CI | P*-value | |
|---|---|---|---|
| Progression-free survival | |||
| FIGO stage | 5.571 | 0.983–31.567 | 0.052 |
| Grade | 2.493 | 0.213–29.171 | 0.467 |
| Lymph node metastasis | 0.700 | 0.190–2.578 | 0.592 |
| Depth of myometrial invasion | 1.766 | 0.286–10.902 | 0.540 |
| LVS involvement | 3.983 | 0.463–34.249 | 0.208 |
| Peritoneal cytology | 8.497 | 1.664–43.376 | 0.010 |
| Wnt7a expression | 0.193 | 0.019–1.955 | 0.164 |
| Overall survival | |||
| FIGO stage | 1.734 | 0.469–6.407 | 0.409 |
| Grade | 0.839 | 0.080–8.844 | 0.884 |
| Lymph node metastasis | 0.846 | 0.238–3.006 | 0.797 |
| LVS involvement | 7.683 | 0.867–68.043 | 0.067 |
| Peritoneal cytology | 5.082 | 1.258–20.525 | 0.022 |
| Wnt7a expression | 0.737 | 0.116–4.696 | 0.747 |
FIGO: International Federation of Gynecology and Obstertics; LVS: lymph vascular space; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval and *Cox regression test.